At-home COVID-19 treatments, especially Pfizer’s Paxlovid, are seen as possible game-changers for the pandemic. The emergency use authorization comes as the U.S. sees a surge in new COVID-19 cases and hospitalizations largely driven by the Omicron variant.

Driving the news: Pfizer released new data last week confirming Paxlovid reduced the risk of hospitalization or death by 89% in high-risk adults, Axios’ Tina Reed reports.

An interim analysis of a second study of the pill that has so far shown a 70% reduction in hospitalization among standard-risk adults, Pfizer said.

Pfizer also believes the Paxlovid treatment will work well against the Omicron variant because of the way the drug works.